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ABSTRACT
Background: Few studies have examined the correlates of breast cancer-related symptoms that
persist posttreatment and determined the relationship between symptoms and quality of life
(QOL).
Methods: A population-based sample of women in the United States with stage 0–II breast
cancer (n  1372) completed a survey including the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire and the Breast Cancer-Specific Quality of
Life Questionnaire. Described are the presence and frequency of 13 symptom scales and their
associations with 10 QOL dimensions.
Results: All study participants had completed primary treatment (surgery and radiation
and/or chemotherapy, if applicable). Mean time from initial surgical treatment to completion
of the questionnaire was 7.2 months (range 0.5–14.9 months). Mean number of symptoms re-
ported was 6.8, with the 5 most common symptom scales being systemic therapy side effects
(87.7%), fatigue (81.7%), breast symptoms (72.1%), sleep disturbance (57.1%), and arm symp-
toms (55.6%). Younger age and poorer health status at diagnosis were associated with worse
symptoms. Fatigue had the greatest impact on QOL, with significant differences between those
with high and low fatigue across 7 QOL dimensions. Sociodemographic, prior health status,
clinical, and treatment/diagnostic factors explained only 9%–27% of the variance in QOL out-
comes. Adding symptom experience increased the variance explained to 18%–60%.
Conclusions: More attention to the reduction and management of disease and treatment-re-
lated symptoms could improve QOL among women with breast cancer.
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INTRODUCTION
WOMEN WITH A DIAGNOSIS OF BREAST CANCERrepresent one of the largest groups of can-
cer survivors, comprising about 22% of the nearly
10 million cancer survivors in the United States.1
In fact, one of the priorities highlighted in the
National Cancer Institute’s 2003–2004 Annual
Report on Cancer Survivorship was that “the
transition from active treatment to social reinte-
gration is crucial and should receive specific at-
tention in survivors’ care.”2 Although the major-
ity of the literature has focused on treatment and
supportive care provided to women during the
initial treatment phase, far less attention has been
given to improving recovery and quality of life
(QOL) on completion of primary treatment. Evi-
dence suggests that even after primary treatment
women continue to experience QOL concerns, in-
cluding emotional distress, fear of recurrence,
and difficulties resuming family, work, and so-
cial roles.3 Women who are highly distressed dur-
ing early survivorship report poorer long-term
adjustment outcomes.4
Studies have found that many symptoms per-
sist after completion of primary breast cancer
treatment, including problems with fatigue,5,6
pain,7 lymphedema,8–10 menopausal symp-
toms,11–15 and sleep disturbance.16–18 In particu-
lar, fatigue has been reported by women irre-
spective of treatment course.5,6,19 Most studies
have focused on individual symptoms or a
unique subset of symptoms (i.e., menopausal)
rather than examining the relative impact of a wo-
man’s collective symptom experience on QOL.
Examining the correlates of symptom experience
on population subgroups has usually involved a
limited number of sociodemographic characteris-
tics or various aspects of the treatment course.
Some studies have suggested that symptom expe-
rience differs by age,6,7,20–22 education,21,23,24 in-
come,25 and race/ethnicity.25 Symptom experience
has also been purported to vary by type of treat-
ment, although the evidence is mixed.21,23,26,27
Whereas some researchers have found very little
variation in physical symptoms and side effects
across some combinations of treatment, for 
example, surgery (lumpectomy or mastectomy),
chemotherapy, and radiation therapy,23,27 others
have found that symptom reporting varies by treat-
ment modality and over time.21,26
Few studies have examined the association of
women’s symptom experience with their QOL as-
sessment. Ganz et al.26 explored the extent to
which symptoms contribute to the assessment of
physical and mental well-being among 558 wo-
men completing primary treatment. The authors
concluded that such symptoms as muscle stiff-
ness, breast sensitivity, aches and pains, tendency
to take naps, and difficulty concentrating were
common among women finishing primary treat-
ment and were statistically significantly associ-
ated with poor physical and emotional well-be-
ing. Arndt et al.28 targeted women in early
survivorship using a comprehensive cancer-spe-
cific measure of symptoms and QOL to assess the
relative impact of symptom experience across
QOL domains. The study measured the relation-
ship between symptom experience and QOL
among 314 women in Germany 1 year after pri-
mary treatment for breast cancer. Fatigue was
found to be the strongest predictor of QOL.
Gaining a better understanding of the symp-
tom experience and its impact on QOL may in-
form intervention strategies to assist women in
this vulnerable stage of breast cancer survivor-
ship. The objectives for this research study were
(1) to describe the symptom experience of women
following primary breast cancer treatment, (2) to
determine the correlates of breast cancer symp-
toms, and (3) to examine the relationship of




The study population consisted of women di-
agnosed with ductal carcinoma in situ (DCIS) and
invasive, nonmetastatic breast cancer in the
greater metropolitan areas of Detroit, Michigan,
and Los Angeles, California. Women were iden-
tified using the Surveillance, Epidemiology, and
End Results (SEER) registries in Detroit and Los
Angeles between December 2001 and January
2003. All cases of DCIS and an approximate 20%
random sample of invasive cases were selected in
both cities. Eligibility criteria included (1) age 
79 years, (2) a primary diagnosis of breast cancer
treated with a definitive surgical procedure, and
(3) ability to complete a written or telephone sur-
vey in English or Spanish. African American wo-
men with invasive disease were oversampled to
increase their representation to approximately
SYMPTOMS AND QUALITY OF LIFE IN BREAST CANCER 1349
one third in Detroit and 20% in Los Angeles. Be-
cause Asian women in Los Angeles were being
approached for other studies during the project
period, they were not recruited for this study.
Women were also excluded if they had a previous
history of primary breast cancer, had metastatic
disease, or had a diagnosis of lobular carcinoma
in situ (CIS). For the purposes of this study, we
also excluded women who had not completed
their primary treatment course for breast cancer
(i.e., surgery and radiation and/or chemother-
apy, if applicable). 
Once SEER staff members identified potential
participants, the following protocol was initiated.
Physicians were notified of our intent to contact
patients (1% were excluded due to physician
concerns), and an introductory letter was sent to
potential participants, followed by a phone call
to assess eligibility. A questionnaire and a $10
coupon for a local grocery store were mailed to
all who agreed to participate and met eligibility
criteria. The Dillman method was used to en-
courage response rates,29 involving a postcard re-
minder for nonrespondents at 2 weeks, a second
letter and survey at 6 weeks, and a follow-up
phone call at 10 weeks. At the follow-up phone
call, nonrespondents were offered, if they pre-
ferred, a short telephone survey.
After removing personal identifiers, the SEER
sites sent completed surveys to the research team
at the University of Michigan for data entry and
analysis. Subsequently, SEER pathology and sur-
vey data were merged using a unique patient
identification number. The study protocol was
approved by the Institutional Review Boards of
the University of Michigan, Wayne State Univer-
sity, and the University of Southern California.
Study measures
Symptom experience and health-related QOL.
Symptom experience and QOL were assessed us-
ing the European Organization for Research and
Treatment of Cancer Quality of Life Question-
naire (EORTC QLQ-C30)30 and the Breast Can-
cer-Specific Quality of Life Questionnaire (QLQ-
BR23).31 The EORTC QLQ-C30 version 2 consists
of 30 questions addressing five functional do-
mains (physical, emotional, role, social, cogni-
tive), one global QOL domain, three symptom do-
mains (fatigue, pain, nausea/vomiting), and six
single items (sleep disturbance, dyspnea, appetite
loss, constipation, diarrhea, financial impact). The
JANZ ET AL.1350
breast cancer-specific supplement (QLQ-BR23)
consists of 23 items, including two functional do-
mains (body image, sexual functioning), three
symptom domains (breast symptoms, arm symp-
toms, systemic therapy side effects), and three
single items (future perspective, sexual enjoy-
ment, upset by hair loss). Respondents were
asked to report if they had experienced symp-
toms, using the past week as a time frame, with
possible responses as yes/no or a 4-point scale (1,
not at all, to 4, very much), except for items re-
lated to sexual functioning and enjoyment, where
the time frame was during the past 4 weeks. For
all items within the EORTC QLQ-C30 and the
QLQ-BR23, higher scores indicate better QOL
(i.e., better functioning) but worse symptom ex-
perience. The psychometric properties of the
EORTC and QLQ-BR23 have been well estab-
lished with excellent reliability and validity. Both
instruments have been used with breast cancer
patients.32,33
A major advantage of the EORTC QLQ-C30 is
the considerable work that has been published on
interpretation of clinically relevant difference
scores.34,35 Osoba et al.35 found that patients with
breast and lung cancer who reported a small
change or a moderate change in symptom expe-
rience over time also reported a corresponding
mean change of 5–9 points or 10–20 points on
their QLQ-C30 scores, respectively. Based on
these results, we set the criterion of a between-
group difference of 10 or more points to repre-
sent a clinically meaningful difference.
Additional variables. Information on sociodemo-
graphic characteristics, prior health status, clini-
cal factors, and breast cancer treatment/diagnos-
tic factors were also obtained from survey data.
Sociodemographic characteristics of interest in-
cluded age at the time of breast cancer diagnosis,
race, education level, total yearly household in-
come, and marital status.
Prior health status variables included the self-
reported number of comorbid conditions (chronic
bronchitis, heart disease, diabetes, high blood
pressure, stroke, arthritis) and health status at
time of diagnosis rated on a 5-point scale (poor,
fair, good, very good, excellent).
Clinical factors included breast cancer stage us-
ing American Joint Committee on Cancer crite-
ria,36 and the time interval between primary
breast cancer surgery and completion of the 
survey.
Treatment/diagnostic factors included initial
surgical treatment (mastectomy with and with-
out reconstruction vs. breast-conserving surgery
[BCS]), whether or not axillary node dissection
was done, and receipt of chemotherapy, radiation
therapy, and/or hormone therapy. SEER sum-
mary information was used to determine if a wo-
man had axillary node dissection as well as to fill
in missing data from participant self-report for
the following measures: age at diagnosis, race,
marital status, response time from date of diag-
nosis to survey completion, primary surgical
treatment, chemotherapy, and radiation therapy.
Statistical methods
The data were weighted to account for the sam-
pling design and to correct for nonresponse. To
account for those women who could not be
reached by mail or telephone, we used a weight
of 0.9 to reflect imputed eligibility if we had made
contact. Descriptive statistics were performed to
characterize the distribution of the variables for
the sample. In addition, in order to describe the
symptom experience of women with breast can-
cer, we constructed indicator variables for each
symptom item within the 13 symptom scales. We
also constructed an indicator variable for each of
the 13 symptom scales, defined as endorsing at
least one item within the set of items represent-
ing the scale.
Using a linear transformation as instructed by
the EORTC QLQ scoring manual, we created 10
QOL scales (physical, emotional, social, role, and
cognitive functioning, global QOL, future per-
spective, body image, sexual functioning, sexual
enjoyment). Additionally, we created a scale for
the 13 symptom domains, of which 6 are multi-
item scales (fatigue, pain, nausea/vomiting, sys-
temic therapy side effects, breast symptoms, arm
symptoms) and the remaining are single item
scales (sleep disturbance, dyspnea, appetite loss,
constipation, diarrhea, financial impact, upset by
hair loss). All scales (QOL, multi/single item
symptom scales) ranged from 0 to 100, with
higher scores indicating better QOL and worse
symptom experience.
Analysis of covariance (ANCOVA) was used
to test for associations between symptom scales
and sociodemographic, prior health status, clini-
cal, and treatment/diagnostic factors, as well as
for associations between symptom scales and
QOL outcomes. Only scales that were endorsed
by at least 50% of our analytical sample were in-
cluded in these analyses. We also calculated esti-
mates of the mean difference in QOL between the
90th (high symptom experience) and 10th (low
symptom experience) percentile of each symptom
scale after adjusting for sociodemographic, prior
health status, clinical, and treatment/diagnostic
factors. We considered between-group differ-
ences that were statistically significant and 10 or
more points to be clinically meaningful differ-
ences. Because all hypotheses were specified a pri-
ori, no adjustments were made for multiple com-
parisons. However, p  0.001 can be viewed as
statistically significant by the most conservative
methods of adjustment for multiple comparisons.
All analyses were performed using SAS version
8.2 (SAS Institute, Cary, NC).
RESULTS
Of the 2640 cases identified through the SEER
registries, 88% (n  2323) were eligible, and
74.3% completed the survey (77.0% from Los An-
geles and 77.9% from Detroit). The percent of wo-
men who were ineligible due to death/illness, no
definitive surgical procedure at contact, or lan-
guage barrier were similar across sites. Among
those women who completed the survey, 93%
completed the written survey, and 7% completed
an abbreviated telephone survey. Nonrespon-
dents were more likely to be nonwhite and older
and have advanced disease. Additional exclu-
sions from the 1844 participants in the final study
were made based on the specific aims of this sub-
study, including 141 women who had completed
the telephone survey where QOL measures were
not available, 148 women with late stage disease
(stage III), and 183 women who had not com-
pleted their primary treatment course (i.e.,
surgery and radiation and/or chemotherapy). A
total of 1372 women were retained for our final
analytical sample.
Table 1 summarizes the sociodemographic and
treatment characteristics of our study sample.
The cutoff points for age were 45 years, 45–54
years, 55–64 years, and 65 years of age. About
37% of women were 65 years of age, and almost
9% were 45 years of age. The racial breakdown
was 70.4% non-Hispanic white, 15.2% non-His-
panic African American, and 14.4% other, of
which 85% were Hispanic. The majority of our
sample was married or with a domestic partner
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and with some college education. Approximately
41% of women reported an income of at least
$50,000, 28% reported an income between $25,000
and $49,999, and 20% reported an income
$25,000. About two thirds of the women re-
ported fewer than two comorbid conditions, and
a little over half reported very good/excellent
health status at time of diagnosis. About 26% of
women had stage 0, 48% stage I, and 26% stage
II breast cancer. The mean time from initial
surgery was 7.2 months (range 0.5–14.9 months).
Approximately 70% of women received BCS, and
30% had a mastectomy. Of those who had a mas-
tectomy, 42.8% had reconstruction. About 74% of
women in the sample had axillary node dissec-
tion. All women had completed primary treat-
ment, 62% had completed radiation (most of
these women had BCS), and 27% had completed
chemotherapy. At the time women filled out the
questionnaire, 56% reported being on hormone
therapy.
Table 2 summarizes the means and standard
deviations (SD) of all symptom and QOL scales.
Cronbach’s alphas for the QOL dimensions and
multi-item symptom scales were primarily 0.60
(physical functioning 0.65; emotional 0.88; role
0.87; social 0.84; cognitive 0.69; body image 0.88;
sexual functioning 0.79; global health 0.92; fatigue
0.84; pain 0.80; systemic therapy side effects 0.41;
nausea/vomiting 0.63; breast symptoms 0.77;
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TABLE 1. CHARACTERISTICS OF WOMEN IN STUDY (N  1372)a
Characteristics n (% weighted) Characteristics n (% weighted)
Sociodemographics Clinical factors
Study site Cancer stage
Los Angeles 729 (52.4) 0 598 (25.7)
Detroit 643 (47.6) I 482 (48.0)
Age
Mean age, years (SD)b 60.5 (10.7) II 253 (26.3)
45 141 (8.9) Mean time from initial surgery to 7.2 (2.5)
45–54 330 (21.9) completion of questionnaire,
55–64 420 (32.1) months (SD)b
65 481 (37.1) Treatment/diagnostic factors
Race Primary surgical treatment
White, (non-Hispanic) 917 (70.4) Breast-conserving surgery 942 (70.1)
African American, (non-Hispanic) 258 (15.2) Mastectomy 430 (29.9)
Other 191 (14.4) Axillary node dissection
Education Yes 779 (61.8)
Less than high school 174 (13.1) No 593 (38.2)
High school diploma 299 (22.7) Radiation therapyc
Some college or beyond 885 (64.2) Yes 828 (73.8)
Income No 544 (26.2)
$25,000 275 (19.7) Chemotherapyc
$25,000–$49,999 383 (28.1) Yes 276 (27.3)
$50,000 560 (41.0) No 1091 (72.7)
Unknown 154 (11.2) Hormone therapyd
Marital status Yes 698 (55.9)
Currently married/domestic partner 815 (60.1) No 662 (44.1)
Divorced/separated/widowed 449 (33.0)






Health status at diagnosis
Poor/fair 170 (12.2)
Good 449 (33.5)
Very good/excellent 734 (54.3)
aSample size is unweighted, percents are weighted; less than 3% missing data across all variables.
bSD, standard deviation.
cFor radiation therapy and chemotherapy, Yes indicates number of women who had completed treatment.
dFor hormone therapy, Yes indicates number of women who had started or finished treatment.
arm symptom 0.74). Scale scores incorporate not
only the presence or absence of the symptom but
also the frequency, a further indication of impact
on QOL. Among the scales, women reported the
highest scores (worse symptom experience) for
fatigue and sleep disturbance and the lowest
mean QOL scores for sexual functioning, sexual
enjoyment, and future perspective.
The individual symptoms reported by women
are summarized in Figure 1. Identified at the bot-
tom of Figure 1 are the individual items with their
associated symptom scales. Among the individ-
ual symptoms, feeling tired was endorsed by the
largest proportion of women (75.5%), followed by
needing rest (66.2%), hot flashes (62.3%), sleep
disturbance (57.1%), and pain in the area of the
breast (52.5%). Far fewer women reported expe-
riencing swollen arms, nausea/vomiting, or di-
arrhea. By creating an indicator variable for each
symptom scale, we found that 50% of women
reported experiencing at least one symptom
within the following scales: systemic therapy side
effects (87.7%), fatigue (81.7%), breast symptoms
(72.1%), arm symptoms (55.6%), and pain (51.7%)
(data not shown). The mean number of symptom
scales endorsed was 6.18 (range 1–13), and 5%
of women reported less than three symptoms.
In an effort to focus on the symptoms that were
most often reported by women, all further analy-
ses were restricted to the 6 symptom scales re-
ported by at least 50% of the sample. Table 3 sum-
marizes the statistically significant and clinically
meaningful results from ANCOVA models re-
gressing each of these symptom scales on so-
ciodemographic, prior health status, clinical, and
treatment/diagnostic factors. Only the clinically
meaningful results are highlighted. With respect
to sociodemographic factors, clinically meaning-
ful differences (10 point difference) were only
present for age, with younger women (45 years
of age) experiencing worse fatigue, pain, and
breast symptoms than those women 65 years of
age. Health status at diagnosis was the measure
most consistently associated with breast cancer
symptom experience, with women who reported
good or very good/excellent (compared with
those who reported fair/poor) health status at di-
agnosis having better symptom experience re-
lated to fatigue, sleep disturbance, and pain. With
regard to cancer stage, women with more ad-
vanced disease at diagnosis reported less sleep
disturbance. Treatment/diagnostic differences in
symptom experience were primarily a function of
chemotherapy, with women who had chemother-
apy having more problems with sleep. There
were no clinically meaningful differences in
symptom experience between women who re-
ceived mastectomy and those who received BCS.
Together, these sociodemographic, prior health
status, clinical, and treatment/diagnostic factors
explained between 7% and 17% of the variability
in symptom experience.
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TABLE 2. MEAN (SD) OF SYMPTOM SCALES AND QUALITY OF LIFE DIMENSIONSa
Symptom scalesb Mean (SD) Qualify of Life Dimensionsc Mean (SD)
EORTC QLQ-C30
Fatigue 28.71 (22.4) Physical functioning 82.57 (21.6)
Sleep disturbance 27.35 (27.9) Emotional functioning 75.52 (21.4)
Pain 17.90 (22.9) Role functioning 82.59 (24.4)
Dyspnea 14.20 (23.0) Social functioning 86.57 (21.2)
Constipation 13.22 (22.2) Cognitive functioning 82.51 (20.8)
Appetite loss 8.77 (18.4) Global quality of life 71.40 (20.4)
Nausea and vomiting 4.35 (12.0)
Diarrhea 6.23 (15.6)
Financial impact 17.90 (27.6)
EORTC QLQ-BR23
Systemic therapy side effects 18.47 (15.3) Future perspective 62.14 (29.1)
Breast symptoms 18.23 (18.5) Body image 84.60 (21.8)
Arm symptoms 15.15 (19.5) Sexual functioning 20.86 (21.4)
Upset by hair loss 14.43 (29.2) Sexual enjoymentd 51.64 (29.1)
aAll symptom scales and quality of life dimensions scored from 0 to 100.
bHigher scores for symptom scales indicate worse symptom experience.
cHigher scores for quality of life dimensions indicate better quality of life.







































Table 4 shows the mean differences in QOL
outcomes between the 90th (high symptom ex-
perience) and the 10th (low symptom experience)
percentiles of each symptom scale after adjusting
for sociodemographic, prior health status, clini-
cal, and treatment/diagnostic factors and other
symptoms scales. In general, higher symptom
scale scores were associated with decreased QOL
outcomes. Fatigue had the most impact on QOL
outcomes, with clinically meaningful differences
between the 90th and 10th percentiles for 7 QOL
dimensions (all differences  15 points). For ex-
ample, for role functioning the average score for
women with high fatigue (90th percentile) was
27.84 points lower than that of women with low
fatigue (10th percentile). Other clinically mean-
ingful differences were evident with respect to
sleep disturbance (for emotional functioning),
pain (for physical, social, and role functioning),
systemic therapy side effects (for cognitive func-
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TABLE 3. RESULTS OF MULTIPLE LINEAR REGRESSION MODELS OF SYMPTOMS SCALES AND SOCIODEMOGRAPHIC, 
PRIOR HEALTH STATUS, CLINICAL, AND TREATMENT/DIAGNOSTIC FACTORSa
Systemic
Sleep therapy side Breast Arm
Characteristic Fatigue disturbance Pain effects symptoms symptoms
Sociodemographicsc
Age, years
45 12.76*** 8.72* 15.15*** 8.60*** 9.99*** 8.71***
45–54 7.01*** 6.08* 9.37*** 6.15*** 8.75*** 6.57***
55–64 4.34** 4.85* 6.44** 4.00*** 4.51*** 3.34*
65 (reference)
Prior health status
Health status at diagnosis
Poor/fair (reference)
Good 11.25*** 15.85*** 13.66*** 5.50*** 5.68** 7.67***




I 2.74 4.30 1.35 0.60 1.55 0.73




Mastectomy 0.94 5.92* 2.06 3.03 1.15 2.82
Axillary node dissection
No (reference)
Yes 1.15 3.06 0.37 2.65 2.80 3.73*
Chemotherapy
No (reference)
Yes 8.67*** 10.67*** 0.94 8.54*** 2.25 0.26
Radiation therapy
No (reference)
Yes 0.04 2.87 1.11 2.12 9.22*** 1.58
Hormone therapy
No (reference)
Yes 0.69 1.14 1.94 2.07* 1.08 0.65
R2 0.15 0.07 0.13 0.17 0.14 0.13
aAll symptom scales scored from 0 to 100.
bValues represent mean differences in QOL outcomes between high (90th percentile) and low (10th percentile, 
reference). Values in bold indicate clinically meaningful findings, as defined by a 10 difference on a scale from 0 to
100. Model also adjusts for study site, race, education, income, marital status, cancer stage, axillary node dissection,
number of comorbidities, and time from treatment.

































































































































































































































































































































































































































































































































































































































































































































































































tioning), and breast symptoms (for body image).
Table 4 also compares the percent of the vari-
ability in our QOL dimensions explained by all
sociodemographic, prior health status, clinical,
and treatment/diagnostic factors with and with-
out symptom experience in the model. The so-
ciodemographic, prior health status, clinical, and
treatment/diagnostic factors explained only
9%–27% of the variability in QOL outcomes. The
addition of symptom experience markedly in-
creased the variance explained to between 18%
and 60%. For example, the variance explained in
role functioning increased from 0.18 to 0.60 when
symptom experience was added to the model.
The only two outcomes where adding symptom
experience produced only minor increases in
variance explained were sexual functioning and
sexual enjoyment.
DISCUSSION
The findings from this large population-based
study provide further insight into the symptom
experience and its impact on QOL among women
who have completed primary treatment for
breast cancer. During the vulnerable period of
transitioning to survivorship, it is apparent that
women continue to experience multiple symp-
toms.26 Over half of the women in our study re-
ported symptoms related to fatigue, hot flashes,
sleep disturbance, general pain, and breast dis-
comfort. In another multisite study, Ganz et al.26
reported similar findings on the symptom expe-
rience of women at the end of primary treatment:
60% reported aches and pains, 60% reported hot
flashes, and 56% reported breast sensitivity. In
general, sleep disturbance has been noted in can-
cer patients17 but seems to be particularly prob-
lematic for breast cancer patients, with 38%–61%
reporting sleep difficulties.16 Findings from other
studies show variation in the persistence of these
symptoms. King et al.21 found that women re-
ported significant improvements in fatigue, pain,
and chest and breast symptoms between 3
months and 1 year after breast cancer surgery.
However, Hartl et al.37 surveyed women with
breast cancer an average of 4.2 years after treat-
ment using the EORTC QLQ-C30 and found that
the most frequent complaints continued to be
sleep disturbance, fatigue, and pain.
Our findings suggest that sociodemographic
characteristics generally do not help define wo-
men who will have greater or lesser symptom ex-
perience following breast cancer treatment. The
only clinically meaningful exception was present
when comparing younger and older women. In-
dependent of other baseline health status and
treatment-related factors, younger women had
worse symptom experience. The finding that
breast cancer has a disproportionate negative im-
pact on younger women (45 years of age) has
been reported by others.20,21,38 Although we con-
trolled for treatment in our analyses, approxi-
mately 46% of women 45 years of age were
treated with chemotherapy. Menopausal transi-
tion for younger women has been associated with
decreases in QOL.20 Previous studies have of-
fered potential explanations for why younger
women may report greater declines in QOL.
These include that younger women may feel
more vulnerable,20,39 experience more emotional
distress,20 have greater fear of death,40 have more
disruptions in their daily activities and finances,39
and possess fewer coping strategies.20
Results from this study lend support to re-
search suggesting that sociodemographic, prior
health status, clinical, and treatment/diagnostic
factors explain only a modest amount of the vari-
ance in QOL among women following comple-
tion of primary treatment.28,41 Additionally, we
found that women’s symptom experience had a
significant impact across a number of dimensions
of QOL. In particular, higher levels of fatigue
were associated with substantial reduction across
multiple domains of QOL. The important contri-
bution of fatigue to QOL has been documented
previously. Baron et al.42 found that persistent
fatigue following breast cancer treatment inter-
fered with functioning and had a negative effect
on physical, mental, and psychological well-be-
ing. A recent study reported that after adjusting
for age, severity of fatigue explained approxi-
mately 30%–50% of the variability across func-
tional areas.28 In addition, Bower et al.6 reported
that approximately one third of breast cancer sur-
vivors had severe fatigue, which was associated
with significantly higher levels of depression,
pain, and sleep disturbance.
Other symptoms that contributed substantially
to QOL after primary treatment included sleep
disturbance, pain, and systemic therapy side ef-
fects. In addition to fatigue, Arndt et al.28 found
that pain, systemic therapy side effects, and arm
symptoms were the symptoms most highly cor-
related with QOL. Others have reported that
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breast cancer patients with significant sleep prob-
lems have reduced ability to perform work and
accomplish physical tasks.18 Although we did not
find a clinically important relationship between
pain and type of surgical treatment, others have
suggested that the pain secondary to surgery or
radiation can be a strong predictor of fatigue6
and, if it persists, can cause considerable disabil-
ity and psychological distress.43 Finally, our re-
sults on the impact of symptoms on QOL are con-
sistent with those of a study conducted by Ganz
et al.,26 which concluded that the severity of
symptoms experienced by women after primary
treatment was significantly related to physical
and mental well-being.
Several previous studies have noted that wo-
men report difficulties with sexual functioning
and sexual enjoyment following completion of
primary treatment for breast cancer.44,45 Our re-
sults suggest that symptoms do not play a ma-
jor role in understanding changes in sexual
functioning. It is important to note that some
symptoms, such as vaginal dryness, were not
measured in this study. Previous studies have
reported that lack of desire, greater body image
problems, difficulty with arousal, and partner-
related issues are important contributors.39,45 In
a recent review of the literature for breast can-
cer survivors 5 years or more postdiagnosis,
Mols et al.46 concluded that although most wo-
men reported good QOL, one of the problems
that could persist was difficulties with sexual
functioning.
Limitations
Our study findings are limited by the cross-sec-
tional design and absence of baseline symptom
and QOL assessment prior to breast cancer diag-
nosis. Therefore, one has to interpret any attri-
bution of symptoms to breast cancer and its treat-
ment with some caution. A previous study by
Schou et al.47 that compared women with breast
cancer to a general female population found that
some of these symptoms are common to women
in this age group. In addition, the generalizabil-
ity of our findings to nonwhite racial/ethnic
groups is somewhat compromised by the practi-
cal limitation imposed by excluding Asian wo-
men at one site and the relatively small sample
of racial/ethnic groups outside of African Amer-
icans. Although we measured a number of co-
morbidities and health status at diagnosis and
controlled for them in the analyses, we may have
attributed some symptom reporting to breast can-
cer and its treatment that is actually the result of
other conditions, such as age-related menopause.
Finally, some may question the definition of clin-
ically meaningful differences in this study, which
was based on previous work by Osoba et al.35
However, we believe it is important to avoid the
pitfall of a large sample size yielding statistically
significant findings that are not likely to be clin-
ically meaningful.
CONCLUSIONS
The findings of this study have implications for
clinical practice and future research. The fact that
breast cancer symptoms accounted for a signifi-
cant amount of the variability in QOL dimensions
suggests that reducing the symptom burden
should have a positive effect on QOL. Upon com-
pletion of primary treatment, women experience
reduced contact with healthcare providers at a
time when they are still in need of support and
are at risk for adjustment difficulties.26 System-
atic documentation of the presence and severity
of symptoms at the end of primary treatment
would be a reasonable first step. At present, fol-
low-up visits are often focused on detecting
symptoms of recurrence even though recurrence
is uncommon in the early posttreatment period.
For some women, acknowledgment of their
symptoms, counseling about common posttreat-
ment symptoms and their natural history, or
teaching behavioral self-management skills to
deal with symptoms that persist may be all that
is required. An assessment to determine if symp-
toms are worsening, stable, improving, or re-
solved seems warranted by the findings of our
study.
For women experiencing more significant
symptoms at the completion of primary treatment,
further therapy to control persistent symptoms
may be required. For example, pain and stiffness
as a result of axillary surgery can be improved with
physical therapy, and hot flashes can be reduced
with low-dose antidepressants.48 Fatigue has mul-
tiple potential etiologies, but persistent severe fa-
tigue should prompt an evaluation for anemia and
depression. Treating anemia-related fatigue with
hemoglobin has been found not only to improve
fatigue but also to lead to improvements in phys-
ical and emotional well-being.49
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Our findings suggest that assessment and in-
terventions aimed at reducing fatigue, sleep dis-
turbance, and pain should target those patients
in whom these symptoms are most prevalent—
younger women and those with a worse health
status at the time of diagnosis. The fact that so-
ciodemographic factors generally were not as-
sociated with symptom scores or QOL dimen-
sions suggests that assessment and interventions
should be broadly considered across these sub-
groups. Bower et al.6 suggested that focusing ef-
forts on treating symptoms of depression, pain,
and sleep disturbance should prove useful in
combating fatigue. The negative association be-
tween fatigue and QOL highlights the impor-
tance of developing and evaluating behavioral
interventions to treat women with considerable
fatigue. Cimprich and Ronis50,51 found an inter-
vention focused on mental restoration and in-
volving regular exposure to natural environ-
ments was beneficial in counteracting fatigue and
significantly improving cognitive function in
women treated for breast cancer. In addition, dif-
ficulties in sexual functioning and enjoyment
seem to involve a more complicated set of factors
beyond just medical and treatment characteris-
tics, requiring further understanding, investiga-
tion, and intervention.
Early assessment and treatment of symptoms
have the potential to reduce costs and increase
productivity. Two recent papers on the economic
outcomes of breast cancer survivors suggest that
use of health services is frequent and intensive
during the first year52 and among long-term sur-
vivors whose overuse of medical resources for
follow-up seems common.53 Predictors of in-
creased costs of services in the first year included
comorbid illness, type of cancer treatment, de-
pression, and physical function. Our finding that
the negative impact of fatigue and pain, adjusted
for all other factors, was greatest for the QOL di-
mension of role functioning suggests that ad-
dressing these symptoms may hasten return to
usual activities, including work. Further research
is needed to determine if more attention to the
treatment of symptoms can reduce costs and un-
necessary healthcare use. We also need to iden-
tify and target women disproportionately af-
fected by breast cancer and its treatment, such as
younger women and those with poor health sta-
tus at the time of diagnosis, and offer more com-
prehensive interventions to address their unique
needs and concerns.
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